Skip to content

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here. Hide this message

Laboratory Medicine

Test Directory / CA19-9


Brown clotted serum, gel barrier

Common AbbreviationsNA
Tube typeBrown clotted serum, gel barrier
Clinical IndicationCA 19-9 is most useful in the diagnosis and management of patients with pancreatic neoplasia. Although elevated levels of CA 19-9 are not distinctively characteristic of pancreatic cancer, it is currently the single most useful blood test in differentiating benign from malignant pancreatic disorders. The possible success of pancreatic resection and prognosis following surgery may be evaluated using the serum levels of CA 19-9. When used serially, levels of CA 19-9 can predict recurrence of the disease prior to radiographic or clinical findings. CA 19-9 is also elevated in gastric carcinomas and colorectal carcinomas. It is also raised in benign conditions such as pancreatitis, hepatocellular jaundice, cirrhosis and cystic fibrosis.
Specimen TypeBlood
Sample typeSerum
Minimum Volume0.5mL If requesting more than 10 tests please send an additional brown clotted serum sample.
Special PrecautionsNo special requirements
Stability5 days at 20 - 25°C, 14 days at 2 - 8°C and 3 months at -20°C
Turnaround TimeInpatient: 24 hours Outpatient/ GP: 24 hours
LaboratoryYork and Scarborough
Reference Interval0 - 34 KU/L
LimitationsAnalysis should not be performed on grossly haemolysed, icteric or lipaemic samples. The assay is unaffected by biotin < 123 nmol/L or < 30 ng/mL. No interference was observed from rheumatoid factors up to a concentration of 1200 IU/mL. In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found. In addition, special cancer drugs were tested. No interference with the assay was found. In rare cases, interference due to extremely high titers of antibodies to analyte specific antibodies, streptavidin or ruthenium can occur. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.
Internal hospital signage with arrows to Main Reception, Outpatients and Pharmacy

A-Z of Services

Chinese Poland

View all languages >